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A drug (single chemical entity) 
is known by several names. First, 
the chemical name describes its 
structure by standard chemical 
nomenclature. Second, the research 
code number is assigned to the 
drug during pharmacodynamic 
studies in animals, and often dur-
ing early clinical investigation. 
Third, it receives a generic name 
which is often a contraction of the 
chemical name, but which de-
scribes the drug and the class of 
drugs to which it belongs, e.g., 
barbital, phenobarbital, pentobar-
bital, etc. The U.S. Adopted Name 
Council (USAN), composed of rep-
resentatives from the American 
Medical Association, U.S. Pharma-
copeia (USP), National Formulary 
(NF), and Food and Drug Ad-
ministration (FDA) recommends 
generic names for all new drugs. 
Since 1962, the FDA must approve 
all generic names. Before, 1962, 
the generic names were often not 
descriptive of the drug, and were 
confusing and difficult to use (Wil-
son, 1960). Fourth, the drug re-
ceives a trademarked name (brand 
name), designated by a super-
script ® at the end of the name, 
signifying that this name has been 
registered with the U.S. Patent Of-
fice. Only the registrant may use 
the trademarked name for the par-
ticular drug; thus his product is 
distinguished from those of com-
petitors. 
Many older drugs that are public 
domain, or on which the patent 
has expired, are often best known 
by the generic name, e.g., pheno-
barbital. If a prescriber wishes to 
prescribe the phenobarbital pro-
duced by Winthrop Laboratories, 
he uses the trade name Luminal. 
Tetracycline HCl is the generic 
name for a specific antibiotic, 
which may be purchased or pre-
scribed by that name. It is also 
known by certain trade names, e.g. , 
Tetracyn (J. B. Roerig & Co.) , 
Achromycin (Lederle Laborator-
ies), Kesso-Tetra (McKesson Lab-
oratories). Even if a company 
holds an unexpired patent on a 
drug, it may be the only manu-
facturer of. that product, so the 
use of the generic name or the 
trademarked name becomes imma-
terial, e.g., Darvon (propoxyphene 
HCl, Eli Lilly & Co.) and there 
can be no controversy over equiva-
lency. On the other hand, if many 
companies manufacture the same 
drug, in similar dosage form, the 
question arises as to whether all 
these products are equivalent with 
respect to physiological and phar-
macological potency. 
Equivalency of Generic Products 
This is important because in 
many instances the prescriber has 
a choice of designating a product 
by its generic name or by a trade-
marked name. If the generic name 
is used, the pharmacist is permit-
ted to dispense that drug manu-
factured by any company. In this 
method of prescribing the assump-
tion is that all products of a specific 
generic name are equivalent. With 
our present knowledge, however, 
there is doubt whether products 
bearing the same generic name are 
equally efficacious, e.g., sulfisox-
azole (F-D-C Reports, Jan. 2, 
1967) . It may be that the patient 
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will get less than the desired dose, 
because the product does not meet 
labeled claim, or that the drug can-
not be absorbed for some reason, 
e.g., the tablet fails to disintegrate 
or dissolve. If generic products are 
not equivalent, then prescribing, 
either voluntary or by directive, 
becomes a question of good pro-
fessional practice. Forcing a pre-
scriber to prescribe any drug in 
which he does not have confidence 
or with which he has no experi-
ence, is a potentially dangerous 
practice. 
The problem of drug designation 
is further complicated in that any 
manufacturer can obtain a trade-
mark for his products, and since 
all drugs now have generic names, 
both terms lose their power to dif-
ferentiate between the quality of 
drugs. There is a new term coming 
into use, "branded-generics," which 
nicely bridges the gap between 
generic and trademarked drugs. 
Trademarks are now being ob-
tained for both old and new gen-
eric drugs. Comparing statistics be-
tween these two groups of drugs 
becomes a meaningless game of 
numbers. 
In addition, the trademark is 
on the drug, and not on the final 
product (dosage form). Yet, the 
patient is not given micro-packets 
of powder or liquid to take; he re-
ceives a combination of ingredi-
ents, including the drug(s), which 
makes an acceptable physical entity 
that can be conveniently handled, 
taken, or administered. 
Discrepancies in Drug Costs 
The cost of medication is inter-
woven into this controversy. The 
products sold under generic names 
are often less expensive than the 
trademarked products, e.g., 5 mg 
dextroamphetamine sulfate tablets 
may be purchased for as little as 
$1.25 for a bottle of 1,000 tablets, 
or purchased as Dexedrine (Smith, 
Kline & French Laboratories) for 
$22.60 (Drug Topics Red Book 
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1967). This phenomenon of price 
differentials occurs in other fields 
also. 
The cost of medication is con-
founded by the pricing structure 
of many pharmaceutical manufac-
turers. They sell their trademarked 
products to government agencies 
and hospitals at much lower prices 
than to the community pharmacist. 
It was reported that Upjohn Co. 
sold prednisone tablets (5 mg) to 
the Government at $4.94 per 1000 
(F-D-C Rept., July 29, 1967), 
whereas the price to community 
pharmacists was $20.94 (Drug 
Topics Red Book 1967). It was also 
reported that Ciba would give a 
bottle of 1,000 tablets free with the 
purchase of two bottles of 1,000 
tablets of Esidrex (hydrochloro-
thiazide) and Esidrex K (hydro-
chlorothiazide and potassium chlo-
ride). This offer was made to public 
and private hospitals, dispensing 
physicians, but not to pharmacists 
(Weekly Pharmacy Rept., Jan. 2, 
1967). Price cannot be equated to 
quality. If it is, one may ask if the 
manufacturers are making products 
of two different qualities, an ex-
pensive one of higher quality and 
a less expensive one of lower qual-
ity. Recently, E. R. Squibb & Sons 
announced the new price for its 
Sumycin (tetracycline). The prod-
uct now will sell for $4.25 per 
100 capsules (F-D-C Rept., August 
14, 1967). This makes Squibb's 
prices more competitive with ge-
neric products. 
Many of the arguments given 
against the concept of generic 
equivalency arose before the 1962 
Kefauver hearings. These hearings 
resulted in the Drug Amendments 
of 1962 to the Federal Food, Drug 
and Cosmetic Act. These amend-
ments gave new regulatory powers 
to the FDA, and as a result many of 
the problems associated with gen-
eric drugs due to poor manufactur-
ing practices are being reduced or 
eliminated. For example, the num-
ber of drug recalls have been in-
ceasing every year (F-D-C Rept., 
Dec. 5, 1966) , indicating that the 
poorer quality products are being 
forced off the market. 
There are those who would like 
to see products prescribed by gen-
eric name only, and those who op-
pose this concept. The former 
group assumes generic and product 
equivalency; the latter group does 
not agree that products are equiva-
lent. Unfortunately, proponents of 
both sides of the question of ge-
neric equivalency have indulged in 
the luxury of stating half truths. 
Let us take a close look at the 
major arguments presented by the 
opposing sides in the generic equiv-
alency controversy. 
For Generic Equivalency 
1. All generic products are 
equivalent, because they must meet 
USP or NF standards. If they are 
equivalent, then one can buy the 
least expensive product. 
Reply: These compendia set 
standards for purity and identifica-
tion of drugs and pharmaceutical 
adjuvants and for the range of 
drug content in various dosage 
forms. The compendia do not guar-
antee therapeutic efficacy or give 
formulas and directions for manu-
facture of dosage forms sold. Some 
of the tests have limited value, e.g., 
the tablet disintegration test may 
not be a reliable index of drug 
availability from the tablet. In 
some cases, the assay may be mis-
leading, e.g., assay for total iodine 
in Thyroid USP (Brune et al., 1962; 
Gatz, Ginsburg, and Salenger, 
1962; MacGregor, 1961; Williams, 
Meister, and Florsheim, 1963). 
Yet the standards prescribed by 
these compendia generally reflect 
present day manufacturing prac-
tices, because the committees which 
establish the standards include in-
dustrial scientists. 
2. The Defense Personnel Sup-
port Center buys only generic prod-
ucts. If these products are used 
in the Bethesda hospitals and given 
to our Presidents, generals, and 
Congressmen, etc., why are they 
not good enough for everybody? 
Reply: The Defense Department 
buys its drugs under generic names 
based on competitive bidding. Since 
all drugs have generic names, and 
anyone can make generic drug 
products not covered by unexpired 
patents, the bidding is open to all. 
The Defense Department inspects 
the manufacturing facilities before 
accepting any bid. After the prod-
uct is made, representatives from 
the department again come to the 
manufacturer to observe all the 
final tests performed on the prod-
uct. By this procedure the Defense 
Department presumably receives a 
product that meets all its specifica-
tions. Not even a large hospital, 
let alone individual pharmacists, 
can make these inspections. The 
manufacturer of trademarked prod-
ucts competes under this system and 
when successful, sells his trade-
marked product under its generic 
name. 
As the FDA increases the number 
of inspectors and is able to enforce 
its regulations more widely, drug 
products should be of higher qual-
ity, because more manufacturers 
will be operating under good manu-
facturing practices and with suf-
ficient quality control. 
Against Generic Equivalency 
1. The large manufacturers of 
trademarked products are engaged 
in research to improve existing 
drugs and to discover new drugs. 
The prices of their drug products 
must be higher to support this re-
search. The small manufacturers 
of generic products do not engage 
in research, and have never dis-
covered a new drug. 
Reply: The companies who un-
dertake research, do not do it for 
altruistic reasons. They do it to 
gain competitive advantages and to 
make money. This is not to be con-
demned, but do not ask for public 
support for it. Many other indus-
tries do research and support re-
search, e.g., chemical, electrical, 
petroleum, etc., but they ,do not 
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ask for public sympathy. The phar-
maceutical industry's research ef-
forts do not justify the large price 
differentials that often exist many 
years after the product has been 
introduced, even if the successful 
products must pay for the failures. 
Companies that discover a new, 
unique, and useful medicinal can 
obtain a patent which runs for 1 7 
years after the date of issue (about 
three years after application). Dur-
ing this time they have a monopoly 
on this drug, and there is no com-
petition, generic or otherwise. In 
this manner they can protect their 
investment and make a profit. 
2. The large manufacturers of 
trademarked products have better 
quality control and can spend more 
time and money in the pursuit of 
excellence. Their products are 
purer and there is less likelihood 
of contamination. 
Reply: This should be true, but 
they are not immune to mistakes 
and accidental contamination. This 
difference is slowly being reduced 
by increasing FDA inspections, and 
hopefully, this difference will con-
tinue to diminish. Mr. Hansen, 
program operations director of the 
Bureau of Regulatory Compliance 
FDA, stated that there were less 
than 70 recalls per year before 
1962; there were 110 in 1964, 340 
in 1965, and 449 in 1966. Of the 
449 violations in 1966, 351 (78%) 
were due to violations of the good 
manufacturing practice regulations 
(F-D-C Rept., Dec. 5, 1966). 
Purity and control of contamina-
tion is a problem that has plagued 
all manufacturers. Contamination 
due to diethylstilbesterol (Weber 
et al., 1963), estrogen (Hertz, 
1958), selenium (Keller, 1960), 
penicillin, Salmonella, metal parti-
cles in opthalmic ointments, etc., 
have occured in products of both 
large and small manufacturers. 
They are more likely to occur due 
to poor manufacturing practices. In 
1953, a study of vitamin prepara-
tions in Canada showed that sub-
potent products were produced 
more often under conditions of 
inadequate quality control than 
those manufactured under ade-
quate control (Campbell, 1953). 
3. The trademark is the identi-
fication of the manufacturer, and 
says he assumes responsibility for 
the product. 
Reply: True! Many manufactur-
ers are concerned about their 
"good name," and, therefore, may 
exercise better quality control. All 
manufacturers are responsible for 
their products whether they have 
a trademark or not. A trademark, 
however, is not synonymous with 
quality; anyone can obtain trade-
marks for his products. 
4. Physicians, dentists, etc., pre-
scribe by trademark because they 
are familiar with the company and 
its products and know the thera-
peutic results to expect from these 
products. 
Reply: True! But, do they really 
know the company? How much of 
the prescriber's information comes 
from the company representative, 
and how complete is that infor-
mation? Ciba was accused of not 
reporting toxicity data on Elipten 
(amine-glutethimide) (FDA Rept., 
1966). Frosst made an inadvertent 
mistake in its reformulation of 
Dicumerol (bishydroxycoumarin) 
(Lozinski, 1960) . Cannot the 
physician just as well become ac-
quainted with certain companies 
that manufacture nonproprietary 
pharmaceuticals? 
5. Some formula ingredients in 
a dosage form make generic pre-
scribing hazardous for patients with 
certain diseases that require re-
stricted caloric or sodium intake. 
When the physician prescribes by 
trademark, he knows what the pa-
tient will be getting. 
Reply: How does the physician 
know what .the ingredients other 
than the drug are? This informa-
tion is not always readily available 
to the prescriber. The manufactur-
ers do not list tablet formula in-
gredients and their amounts. One 
gram of sugar produces about four 
calories and no tablet would con-
tain this much sugar as a diluent. 
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The prescriber must write to the 
company to ascertain the ingredi-
ents. 
It is possible that a large manu-
facturer may be more concerned 
as to the ultimate user of his pro-
duct, and therefore make adjust-
ments in his formulation, e.g., omit 
calorie producing materials or 
sources of sodium ion. He would 
state this in the package inserts, 
etc. 
6. When a generic product is 
prescribed, the same product is 
not always dispensed. This can lead 
to varying therapeutic results. A 
trademark or designation of the 
manufacturer insures that the same 
product is always dispensed. 
Reply: The same product should 
always be dispensed unless it is no 
longer available. The source of the 
generic product should be noted 
on the prescription order by the 
pharmacist, to insure that the same 
product is dispensed when the pre-
scription order is refilled. 
When a patient is on long term 
drug therapy, e.g., insulin, penicil-
lin, anticoagulants, thyroid, etc., a 
constant drug blood level in the 
therapeutic range is necessary to 
prevent relapse. A reliable product 
which will give the same absorp-
tion pattern is necessary. Changing 
brands may result in different levels 
of the drug in the blood. The sec-
ond brand may be satisfactory for 
a patient just starting on the ther-
apy regimen, but may not be satis-
factory for refilling of a prescrip-
tion order. Dosage adjustment is 
easiest when the patient is just 
starting therapy. The prescriber 
learns what to expect from each 
product regardless of the name. 
7. The pharmacist has greater 
liability when filling prescriptions 
for products prescribed generically. 
Reply: True, but what does this 
have to do with the proper treat-
ment of patients? 
If a trademarked product is pre-
scribed, or the manufacturer of the 
product is stated on the prescrip-
tion order, then the pharmacist has 
no choice as to what to dispense, 
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and he is only liable under the im-
plied warranty doctrine. If a ge-
neric product is requested and the 
manufacturer not designated, then 
the pharmacist has a choice. If he 
uses care and exercises his knowl-
edge and experience to choose a 
reliable product from a source in 
which he has confidence, then he 
cannot be considered negligent, but 
the implied warranty doctrine still 
applies. Since the product is sold 
in interstate commerce, a new drug 
application has been approved by 
the FDA, so that the pharmacist 
does not have to guarantee efficacy. 
When products are prescribed by 
generic name, the pharmacist has 
more responsibility and hence 
more liability, but he should be 
willing to accept this. 
8. Products sold under non-pro-
prietary names do not maintain 
their potency as well as proprietary 
products. 
Reply: This is one of the quick-
est tests that can be performed on 
a product by the FDA or a state 
agency. Judging from the results 
reported in the Medical Letter 
(Aug. 19, 1960), potency is rarely 
outside the set limits. On the other 
hand, taking the data collected by 
the analyst of the city of Birming-
ham, England, it appears that the 
potency of many English products 
does not meet official requirements 
(Bagnall and Stock, 1955). There 
is not sufficient published data 
available at this time to determine 
if this statement is true. 
9. The large manufacturer has 
more staff, facilities, information, 
and manufacturing "know how" 
than the small company. Therefore 
the large manufacturer is better 
able to produce a more stable, 
uniform, and efficacious product. 
Reply: The large manufacturers 
do not have a monopoly on infor-
mation and the small manufac-
turer can hire knowledgeable and 
experienced personnel. The good 
manufacturing practice regulations 
and their interpretation are avail-
able to all. A great deal of stability 
data and incompatibility informa-
tion has been published. Unfortu-
nately, however, the availability of 
this information does not guarantee 
its application. The FDA has this 
knowledge too, and uses it in judg-
ing new drug applications, and in 
their plant inspections. 
The argument does not end here. 
It has been demonstrated many 
times that there are numerous fac-
tors in the formulation and manu-
facture of dosage forms that may 
affect the efficacy of the product. 
Levy and Nelson (1961) and Del-
gado and Cosgrove ( 1963) review 
this problem in detail. These au-
thors discuss the effect of variables 
such as drug particle size, sterility 
of ophthalmic preparations, rubber 
and polymer closures on multidose 
vials, ingredients of ointment and 
suppository bases, salts and esters 
of the parent drug molecules, and 
the ingredients added to the drug 
to permit manufacture of the dos-
age form such as solvent, sufactant, 
and fillers. 
A commonly used filler for tab-
lets and capsules, dicalcium phos-
phate, was found to depress blood 
concentration of tetracycline (Bo-
ger, 1959) . Drug particle size may 
affect absorption of both oral and 
parenteral product (Levy, 1963a), 
e.g., sulfa drugs, griseofulvin, and 
insulin. Increasing the solubility of 
the tablet base increased the ab-
sorption of spironolactone (Levy, 
1962). "Sgft" tablets of pheny-
lindanedione produced drug blood 
levels similar to that produced by 
loose powder in capsules, whereas 
"hard" tablets gave delayed and 
poor absorption (Schulert and 
Weiner, 1954). The salt form of 
PAS and the presence or absence 
of an enteric coating influenced 
the PAS blood level (Frostad , 
1961). The salt form, molecular 
modification, and the formulation 
of aspirin tablets affected the sali-
cylate blood level (Leonards, 1963 ; 
Levy and Gagliardi, 1963; Levy 
and Sahli, 1962). An in vitro test 
to determine the dissolution rate 
of a drug has explained why cer-
tain drug products, such as predni-
sone (Campagna et al., 1963) and 
tolbutamide (Levy, 1963b), were 
reportedly poorly absorbed. In an 
investigation of 18 commerically 
available tolbutamide tablets, it 
was found that the amount of drug 
dissolved at the end of one hour 
varied from 30% to 86% (Brud-
ney, Stewart, and Eustace, 1963). 
In vitro studies (Levy et al., 1963; 
Levy and Gumtow, 1963) have 
shown several factors that influ-
ence the rate of tablet dissolution. 
Studies have shown that in com-
merically available sustained re-
lease products, drug absorption 
may vary from complete absorp-
tion immediately (no sustained ef-
fect) to almost no absorption 
(Shenoy, Chapman, and Campbell, 
1959). 
Stability of a product is impor-
tant not only because the potency 
of the product must be maintained, 
but also because the decomposition 
products may produce untoward 
reactions, e.g., tetracycline (Frimp-
ter et al., 1963; Editorial, J. Am. 
Med. Assoc. , 1963). 
Isolated clinical cases have been 
reported in which a generic pro-
duct gave poorer results than a 
trademarked product, e.g., predni-
sone (Keller, 1960), cortisone 
(Rosenheim and Ross, 1958, Boch, 
19 59; Bayliss, 19 59), tolbutamide 
(Carter, 1963; Caminetsky, 1963), 
and phenylbutazone (Searl and 
Pernarowski, 1967) . Even if in-
effectiveness has not been shown, 
it may still be there. 
We have learned much about the 
formulation and manufacture of 
dosage forms, often only after the 
product has been marketed. Over-
sights, even by large manufactur-
ers, have come to light in this man-
ner. The large manufacturer has 
the personnel and the facilities that 
would seem to make him more 
able to do thorough investigations 
before marketing a product, but 
he has not always done so. 
The large companies also have 
produced drugs for a very limited 
market as a public service, because 
the drug is needed. This is not an 
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argument against generic equiva-
lency. 
Conclusion 
The truth about generic equiva-
lency has not yet been determined. 
The arguments in the generic equiv-
alency controversy are confounded 
by names, proprietary (trademark, 
brand name) as opposed to non-
proprietary (generic, branded-ge-
neric), yet quality of the products 
is not necessarily related to any 
name. The efficacy and not the 
name of the product is important. 
The crucial question to ask is 
whether the product is clinically 
or therapeutically effective, giving 
reliable and uniform results. 
Drugs called by their generic 
names are here to stay and more 
than likely their use will increase, 
especially as state and federal 
governments pay more of the med-
ication bills. Kentucky and Louisi-
ana already have issued lists of 
generic equivalents to trademarked 
products. 
Meanwhile, the prescriber and 
the pharmacist still must ponder 
the question of therapeutic equiva-
Iency of drug products. What prod-
uct is to be requested on a pre-
scription order and what product 
is to be dispensed if the drug is 
prescribed by its generic name. 
More information is needed to an-
swer this question. Clinical trials 
testing the hypothesis of generic 
equivalency are required. A na-
tional clearing house for informa-
tion on the efficacy of drug prod-
ucts may be necessary. A national 
organization such as the American 
Pharmaceutical Association, Amer-
ican Medical Association, or the 
FDA, or an organization composed 
of representatives of interested 
groups could collect and dissem-
inate the information to physicians, 
dentists, pharmacists, etc. 
The U.S. Pharmacopeia and Na-
tional Formulary monographs 
should include formulas and man-
ufacturing directions for the various 
drug products. The specifications 
should be based on clinicaI!y dem-
onstrated efficacy. The monographs 
could also include information on 
known factors that may impair 
the effectiveness of the product. 
Formula and process variations 
would be permitted only if the 
same therapeutic results can be 
demonstrated clinically. 
The knowledge that the Defense 
Department has concerning its 
drug purchases and the use of these 
products in its facilities could be 
made available. Manufacturers, 
both large and small, could make 
available clinical and physiochemi-
cal data on their products, such 
as assay, drug content variation per 
unit dose, tablet dissolution rates, 
drug levels in blood or urine, and 
stability. It is important that the 
FDA or the proper state agency be 
informed of any suspected drug 
products so that substandard prod-
ucts may be removed from the 
market as rapidly as possible. 
Finally, it is necessary that more 
people become aware of the true 
magnitude of the problem of ge-
neric equivalency. Because of the 
present Jack of knowledge of which 
drug products are therapeutically 
equivalent, the prescriber and phar-
macist must rely on their experi-
ence as to which products and 
companies are reliable. They must 
also continually search their journ-
als for information on the thera-
peutic equivalency of products. 
Perhaps the pharmacist should com-
pile information on generic and 
therapeutically equivalent drug 
products, which companies consist-
ently make poor products, using 
sources as Weekly Pharmacy Re-
ports (The Green Sheet), F-D-C 
Reports (The Pink Sheet), FDA 
Papers (U.S. Government Printing 
Office), and The Medical Letter on 
Drugs and Therapeutics. These 
compilations would then be avail-
able for the prescriber. 
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